ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,431.60
-0.04%
US Tech 100
19,194.40
0.14%
다우존스 지수
38,589.16
0.00%
Bitcoin
65,722.25
-1.38%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Salarius Pharmaceuticals Inc (SLRX)

  7. Salarius Pharmaceuticals Inc (SLRX) 뉴스

SLRX

Salarius Pharmaceuticals (SLRX)

Salarius Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:SLRX
일자시간출처헤드라인심볼기업
2024/06/1721:11Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
2024/06/1721:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
2024/06/1721:00GlobeNewswire Inc.Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual MeetingNASDAQ:SLRXSalarius Pharmaceuticals Inc
2024/06/1505:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
2024/06/1221:00GlobeNewswire Inc.Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock SplitNASDAQ:SLRXSalarius Pharmaceuticals Inc
2024/05/1405:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
2024/03/2305:05GlobeNewswire Inc.Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:SLRXSalarius Pharmaceuticals Inc
2024/03/0706:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
2024/02/2306:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRXSalarius Pharmaceuticals Inc
2024/02/2306:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRXSalarius Pharmaceuticals Inc
2024/02/2306:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRXSalarius Pharmaceuticals Inc
2024/02/2222:00GlobeNewswire Inc.Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing ExpensesNASDAQ:SLRXSalarius Pharmaceuticals Inc
2024/01/1622:00GlobeNewswire Inc.Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein DegradersNASDAQ:SLRXSalarius Pharmaceuticals Inc
2024/01/0322:30GlobeNewswire Inc.Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient EnrollmentNASDAQ:SLRXSalarius Pharmaceuticals Inc
2023/11/1007:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
2023/11/0722:30GlobeNewswire Inc.Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development ProgramNASDAQ:SLRXSalarius Pharmaceuticals Inc
2023/10/2804:57Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:SLRXSalarius Pharmaceuticals Inc
2023/09/0706:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
2023/08/1105:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
2023/08/1105:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
2023/08/1105:05GlobeNewswire Inc.Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:SLRXSalarius Pharmaceuticals Inc
2023/08/0905:05GlobeNewswire Inc.Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its ResourcesNASDAQ:SLRXSalarius Pharmaceuticals Inc
2023/07/1222:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
2023/07/1121:30GlobeNewswire Inc.Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma PatientsNASDAQ:SLRXSalarius Pharmaceuticals Inc
2023/06/1221:00GlobeNewswire Inc.Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid CongressNASDAQ:SLRXSalarius Pharmaceuticals Inc
2023/06/0819:02Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SLRXSalarius Pharmaceuticals Inc
2023/06/0720:28Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:SLRXSalarius Pharmaceuticals Inc
2023/06/0206:02Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:SLRXSalarius Pharmaceuticals Inc
2023/05/2706:03Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:SLRXSalarius Pharmaceuticals Inc
2023/05/1705:34Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SLRXSalarius Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:SLRX

최근 히스토리

NYSE
DIS
Walt Disney
CCOM
US100
US Tech 100
CCOM
US500
US 500
NYSE
AXP
American Express
USOTC
BASFY
BASF (QX)
NYSE
MCD
McDonalds
NYSE
NKE
Nike
USOTC
RHHBY
Roche (QX)
NYSE
VZ
Verizon Communications
COIN
BTCUSD
Bitcoin
NYSE
MRK
Merck
AMEX
SPY
SPDR S&P 500
COIN
SOLUSD
Solana
NYSE
KO
Coca Cola
FX
USDGBP
US Dollar vs Sterling
FX
USDEUR
US Dollar vs Euro
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유